Brought to you by 
AZ licenses exclusive global rights to Rigel's R256 for asthma
05 Jul 2012
Executive Summary
Rigel Pharmaceuticals Inc. (inflammatory and autoimmune diseases) has granted AstraZeneca PLC exclusive worldwide rights to develop and sell its preclinical chronic asthma candidate R256, potentially expanding AZ’s already strong respiratory and inflammation offerings.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ licenses exclusive global rights to Rigel's R256 for asthma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice